Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Mesothelioma
Trial Type:  Treatment
Results 1-25 of 37 for your search:
Start Over
Nintedanib (BIBF 1120) in Mesothelioma
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 1199.93, NCI-2013-01643, 2012-005201-48, NCT01907100
Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma
Phase: Phase II, Phase I
Type: Tissue collection/Repository, Treatment
Age: 18 and over
Trial IDs: S0905, NCI-2011-02015, CDR0000665415, SWOG-S0905, NCT01064648
Genetically Engineered Lymphocytes in Treating Patients with Metastatic Cancer or Cancer That Cannot Be Removed by Surgery Receiving Chemotherapy and Aldesleukin
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 66
Trial IDs: 12-C-0111, NCI-2013-01516, 1112-1139, 120111, P11928, RD-12-I-02, NCT01583686
Vaccine Therapy and Iscomatrix with or without Cyclophosphamide and Celecoxib in Treating Patients with Thoracic Malignancies or Tumors That Have Spread to the Chest Cavity
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 14-C-0053, NCI-2014-02465, 140053, 348360, P131392, NCT02054104
A Phase I/IIa Study of BMS-986148 in Subjects With Select Advanced Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CA008-002, NCI-2015-01329, 2014-002485-70, NCT02341625
Genetically Modified T Cells in Treating Patients with Stage III-IV Non-small Cell Lung Cancer or Mesothelioma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2727.00, NCI-2015-00329, 2727, NCT02408016
Pemetrexed Disodium or Observation in Treating Patients with Malignant Pleural Mesothelioma without Progressive Disease after First-Line Chemotherapy
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CALGB 30901, NCI-2011-02023, CDR0000667496, NCT01085630
Vaccine Therapy in Treating Patients with Malignant Mesothelioma Previously Treated with Combined Modality Therapy
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-134, NCI-2010-02375, NCT01265433
Pentostatin, Cyclophosphamide, and SS1(dsFv)-PE38 Immunotoxin in Treating Patients with Mesothelioma, Lung Cancer, or Pancreatic Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-C-0160, NCI-2013-01490, 110160, P10761, 8980, NCT01362790
Erlotinib Hydrochloride in Treating Patients with Malignant Peritoneal Mesothelioma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-0032, NCI-2012-00332, NCT01592383
Plicamycin in Treating Patients with Malignancies Involving the Lungs, Esophagus, or Pleura That Cannot Be Removed by Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-C-0151, NCI-2013-01534, 120151, P12961, NCT01624090
Window of Opportunity Study of VS-6063 (Defactinib) in Participants With Surgical Resectable Malignant Pleural Mesothelioma.
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: VS-6063-203, NCI-2014-00284, NCT02004028
Dendritic Cell Vaccine, Recombinant Interferon Alfa, Rintatolimod, and Celecoxib After Surgery in Treating Patients with Peritoneal Surface Cancers
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: UPCI 12-110, NCI-2014-01357, 02151448, NCT02151448
Chemotherapy With or Without Porfimer Sodium-Based Photodynamic Therapy During Surgery in Treating Patients With Malignant Pleural Mesothelioma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: UPCC 14513, NCI-2014-01242, 819186, NCT02153229
Alisertib in Treating Patients with Malignant Mesothelioma That Cannot Be Removed by Surgery
Phase: Phase II
Type: Treatment
Age: Over 18
Trial IDs: 2014-0497, NCI-2014-02568, X14024, NCT02293005
Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM).
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MORAb-009-201, NCI-2015-01754, NCT02357147
Pembrolizumab in Treating Patients with Malignant Mesothelioma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: IRB14-1381, NCI-2015-00348, NCT02399371
Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 15743, NCI-2015-02207, 2012-003650-88, NCT02610140
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 3475-158, NCI-2015-02278, 2015-002067-41, NCT02628067
Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: MCC-18094, NCI-2016-00002, NCT02611037
Intrapleural Measles Virus Therapy in Treating Patients with Malignant Pleural Mesothelioma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1023, NCI-2011-03574, 2010UC103, Mod1000260438, NCT01503177
Photodynamic Therapy and HPPH in Treating Patients With Pleural Malignancy Who Are Undergoing Surgery
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: UPCC# 02507, NCI-2009-01539, NCT01673074
Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: ADU-CL-02, NCI-2012-03035, NCT01675765
Start Over